Menu

TAKE ACTION WITH VISUDYNE® WHEN YOU SEE
THESE PATIENT TYPES

79-year old VISUDYNE® patient with persistent retinal fluid Not an actual patient

A PATIENT WITH PERSISTENT RETINAL FLUID

EXPAND TO LEARN MORE ABOUT RANDALL

  • Randall
  • 79 years old
  • LOVES TAKING HIS GRANDKIDS ON CAMPING TRIPS

WET AMD JOURNEY

  • At his annual ophthalmology appointment, Randall was concerned about a decrease in his vision.
  • Randall’s imaging led to a diagnosis of predominantly classic subfoveal CNV due to AMD.

INITIAL TREATMENT

  • Randall was on an anti-VEGF injection regimen for 1.5 years, with an improvement in visual acuity from 20/160 to 20/40.
  • Despite anti-VEGF treatment, residual subretinal fluid remained.

Images courtesy of the Retina World Congress image gallery and reference library: www.retinarocks.org.

Why VISUDYNE®?

  • As a patient who was still experiencing persistent fluid, Randall could benefit from another wet AMD therapy option.
  • Randall was given VISUDYNE® to help resolve his persistent retinal fluid and maintain his vision.1,2

AMD=age-related macular degeneration, anti-VEGF=anti-vascular endothelial growth factor, CNV=choroidal neovascularization, SD-OCT=spectral domain optical coherence tomography.

76-year old VISUDYNE® patient with inadequate response to treat-and-extend regimen of anti-VEGF therapy Not an actual patient

A patient with an inadequate response to a treat-and-extend regimen of anti-VEGF therapy

EXPAND TO LEARN MORE ABOUT GLORIA

  • Gloria
  • 76 years old
  • LOVES crossword puzzles and calling bingo

WET AMD JOURNEY

One year ago, Gloria’s vision began to deteriorate, therefore prompting a visit to her ophthalmologist, who suspected wet AMD and referred her to a retina specialist.

INITIAL IMAGING FINDINGS

Gloria’s imaging was consistent with predominantly classic subfoveal CNV due to AMD.

Image source: Front Cell Dev Biol. 2021 Jan 25;8:612812. doi: 10.3389/fcell.2020.612812.

INITIAL TREATMENT

The retina specialist immediately treated Gloria with anti-VEGF therapy. After several monthly injections, her retina specialist extended her treatment interval to every 6 weeks, but Gloria’s BCVA worsened.

Why VISUDYNE®?

  • Gloria’s inadequate visual response to extension of the anti-VEGF treatment interval prompted her retina specialist to choose a new treatment approach.
  • VISUDYNE® was the next treatment choice for the management of Gloria’s wet AMD, offering a different mechanism of action than anti-VEGF treatment.1

AMD=age-related macular degeneration, anti-VEGF=anti-vascular endothelial growth factor, BCVA=best corrected visual acuity, CNV=choroidal neovascularization, SD-OCT=spectral domain optical coherence tomography.

74-year old VISUDYNE® patient with anti-VEGF injection fatigue Not an actual patient

A PATIENT WITH ANTI-VEGF INJECTION FATIGUE

EXPAND TO LEARN MORE ABOUT CATHY

  • Cathy
  • 74 years old
  • volunteers at her local community center

WET AMD JOURNEY

Three years ago, Cathy arranged an appointment at the only retina clinic within 2 hours of her home after she saw wavy lines and blank spots when checking her own vision with an Amsler grid.

INITIAL IMAGING FINDINGS

Cathy’s imaging revealed onset of predominantly classic subfoveal CNV due to AMD.

Images courtesy of the Retina World Congress image gallery and reference library: www.retinarocks.org.

INITIAL TREATMENT

  • Cathy began anti-VEGF therapy with an interval of 4 weeks, and then transitioned to a treat-and-extend regimen, receiving injections approximately every 6 weeks.
  • Over the 3 years, Cathy’s anti-VEGF injection frequency became a burden that disrupted her activities at the community center and ultimately led to injection fatigue.

Why VISUDYNE®?

  • As a patient burdened by the frequency of anti-VEGF injections, Cathy discussed options with her retina specialist that could offer efficacy with fewer office visits.
  • VISUDYNE® was selected as the treatment for Cathy, reducing her frequency of treatment.
  • The physician should reevaluate the patient 3 months after VISUDYNE® treatment and, if choroidal neovascular leakage is detected on FA, therapy may be repeated.1

AMD=age-related macular degeneration, anti-VEGF=anti-vascular endothelial growth factor, CNV=choroidal neovascularization, FA=fluorescein angiography, SD-OCT=spectral domain optical coherence tomography.

HOW VISUDYNE® WORKS

Indication

VISUDYNE® (verteporfin for injection) therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV.

Important Safety Information

  • VISUDYNE® (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any component of this preparation.
  • Standard precautions should be taken during infusion of VISUDYNE to avoid extravasation, including but not limited to:
    • A free-flowing intravenous (IV) line should be established before starting VISUDYNE infusion and the line should be carefully monitored.
    • Due to the possibly fragility of vein walls of some elderly patients, it is strongly recommended that the largest arm vein possible, preferably the antecubital, be used for injection.
    • Small veins in the back of the hand should be avoided.
  • Extravasation of VISUDYNE, especially if the affected area is exposed to light, can cause severe pain, inflammation, swelling or discoloration at the injection site. Necrosis at the injection site following extravasation has been reported. If extravasation does occur, the infusion should be stopped immediately. The extravasation area must be thoroughly protected from direct light until swelling and discoloration have faded in order to prevent the occurrence of local burn, which could be severe. Cold compresses should be applied to the injection site. Oral medication for pain relief may be administered.
  • Following injection with VISUDYNE, care should be taken to avoid exposure of skin or eyes to direct sunlight or bright indoor light for 5 days. If emergency surgery is necessary within 48 hours after treatment, as much of the internal tissue as possible should be protected from intense light.
  • Patients who experience severe decrease of vision of 4 lines or more within 1 week after treatment should not be retreated, at least until their vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by the treating physician.
  • Cases of anaphylactic reactions have been reported. Immediately discontinue VISUDYNE and initiate appropriate therapy if anaphylactic or other serious allergic reactions occur during or following therapy.
  • The most frequently reported adverse events (occurring in approximately 10%-30% of patients) were injection site reactions (including pain, edema, inflammation, extravasation, rashes, hemorrhage, and discoloration), and visual disturbances (including blurred vision, flashes of light, decreased visual acuity, and visual field defects, including scotoma).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for VISUDYNE®.

Indication and Important Safety Information

References: 1. VISUDYNE® (verteporfin for injection) [package insert]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2022. 2. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol. 1999 Oct;117(10):1329-1345.